Novartis India profit and loss

Latest FY25

Revenue: ₹356cr+6.3% on FY24
EBITDA: ₹91.4cr+40.1% on FY24

₹ crore except per share

Tap a line for its trend	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023

Expenses
	356	335	379
	42.0	61.7	58.1
	398	397	437
	—	—	199
	3.8	9.9	2.4
	18.7	23.0	35.6
	0.8	1.5	1.8
	2.2	2.6	6.1
	43.5	46.8	76.0
	268	274	321
	91.4	65.3	65.1
	89.2	62.7	59.0
Profit
	—	—	115
	130	123	115
	30.0	37.6	1.7
	−0.4	0.0	10.3
	29.5	37.7	12.0
	101	85.2	103
	1.0	1.2	3.1
	102	86.4	106
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	—	—	177
	—	—	46.7%
Adjusted (ex-exceptional items) — derived
	—	—	115
	—	—	103

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

NOVARTIND₹1,821.40

Novartis India Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersBPLPHARMA JENBURPH KPL MAKERSL PARNAXLAB SGRL SHUKRAPHAR SUNLOC

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025
Revenue from Operations	378.7	335.1	356.3
Other Income	58.1	61.7	42.0
Total Income	436.9	396.8	398.2
Expenses
+ Purchases of Stock-in-Trade	199.3	—	—
+ Changes in Inventories	2.4	9.9	3.8
+ Employee Benefit Expense	35.6	23.0	18.7
+ Finance Costs	1.8	1.5	0.8
+ Depreciation & Amortisation	6.1	2.6	2.2
+ Other Expenses	76.0	46.8	43.5
Total Expenses	321.5	273.9	267.8
EBITDA	65.1	65.3	91.4
EBIT	59.0	62.7	89.2
Profit
PBT before Exceptional Items	115.4	—	—
Pretax Income	115.4	122.8	130.4
+ Current Tax	1.7	37.6	30.0
+ Deferred Tax	10.3	0.0	-0.4
Tax Expense	12.0	37.7	29.5
Net Income	103.4	85.2	100.9
+ Other Comprehensive Income	3.1	1.2	1.0
Total Comprehensive Income	106.5	86.4	101.9
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	177.1	—	—
Gross Margin %	46.75	—	—
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	115.4	—	—
Net Income Adj (tax-effected)	103.4	—	—

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY25 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.